Rockville, MD, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Based on a new research report published by Fact.MR, the global orally disintegrating tablet market is poised to reach a valuation of US$ 24.45 billion ...
Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The "Orally Disintegrating Tablet Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, ...
An Increase in Demand and Opportunities for the Global Orally Disintegrating Tablet Market by 2024,” offers a comprehensive analysis of the market by evaluating research and information from multiple ...
A US Food and Drug Administration guidance issued Tuesday provides new recommendations to applicants who wish to designate proposed products as orally disintegrating tablets (ODTs). Rockville, MD (Dec ...
Offering a simple set-up specifically for vaginal tablets, the new tester reduces equipment investment costs relative to those associated with generic suppository testing, while at the same time ...
Pharmaceutical testing is a must to ensure that all medications meet the top quality, safety, and performance requirements before they enter the market. CD Formulation’s cGMP-compliant laboratory is ...
This article is part of PharmTech's supplement "API Synthesis and Formulation 2009." New drug-delivery technologies are often championed by contract manufacturing organizations. For new technologies ...
The US Food and Drug Administration (FDA) has approved an amphetamine extended-release orally disintegrating tablet (Adzenys XR-ODT) for the treatment of attention ...
Please provide your email address to receive an email when new articles are posted on . The FDA recently approved Adzenys XR-ODT for the treatment of attention ...
Objective: To compare the flavour and taste preferences of two acid-inhibitory therapies in children. Subjects and Setting: 104 (52 male and 52 female) healthy children aged 6-11 years participated in ...
Neos Therapeutics Inc. recently announced the FDA approved Cotempla XR-ODT, an extended-release orally disintegrating tablet, for the treatment of ADHD in children aged 6 to 17 years. “Cotempla XR-ODT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback